Evidence map›Paper›PMID 30783650›Full record

ArticleEuropean journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery2019

Tumour size determines both recurrence-free survival and disease-specific survival after surgical treatment for thymoma.

Meinoshin Okumura, Ichiro Yoshino, Motoki Yano, Shun-Ichi Watanabe, Masahiro Tsuboi, Kazuo Yoshida, Hiroshi Date, Kohei Yokoi, Jun Nakajima, Shin-Ichi Toyooka and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Meinoshin OkumuraDepartment of General Thoracic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.
Ichiro YoshinoDepartment of General Thoracic Surgery, Chiba University Graduate School of Medicine, Chiba, Japan.
Motoki YanoDivision of Chest Surgery, Department of Surgery, Aichi Medical University, Aichi, Japan.
Shun-Ichi WatanabeDepartment of Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan.
Masahiro TsuboiDepartment of Thoracic Surgery, National Cancer Center Hospital East, Chiba, Japan.
Kazuo YoshidaDepartment of Thoracic Surgery, Shinshu University School of Medicine, Matsumoto, Japan.
Hiroshi DateDepartment of Thoracic Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Kohei YokoiDepartment of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Jun NakajimaDepartment of Thoracic Surgery, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.
Shin-Ichi ToyookaDepartment of General Thoracic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan.
Hisao AsamuraDepartment of Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan.
Etsuo MiyaokaDepartment of Mathematics, Science University of Tokyo, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe tumour, node and the metastasis (TNM) staging system for thymic epithelial tumours was adopted by the Union for International Cancer Control (UICC) in 2016. Although the T factor is defined by the invasive nature of a thymoma, tumour size is not considered. The aim of this study was to examine the clinical importance of tumour size using a nationwide retrospective database of cases treated from 1991 to 2010 compiled by the Japanese Association for Research of the Thymus.

methodsTumour size was evaluated by the maximum diameter shown by computed tomography imaging prior to resection. Tumour size was available for 2083 thymoma patients undergoing upfront surgical treatment. The tumour size ranged from 0.6 to 19.4 cm (mean 5.1 cm, median 4.9 cm). Harrell's C-index was adopted to determine the cut-off value of the tumour size in 0.5-cm increments.

resultsThe highest C-index value (0.7760) was obtained in terms of recurrence-free survival after the complete resection when the cut-off value was set at 5.0 cm. The 10-year recurrence-free survival rate was 93.8% in patients with a tumour ≤5.0 cm and 84.3% in patients with a tumour >5.0 cm (P < 0.0001). The highest C-index value (0.8885) in terms of disease-specific survival was obtained when the cut-off value was set at 8.0 cm. The 10-year disease-specific survival rate was 98.8% in patients with a tumour <8.0 cm and 90.1% in those with a tumour ≥8.0 cm (P < 0.0001). The Cox's proportional hazard model analysis showed that the tumour size and the TNM-based pathological stage were independent factors to determine both recurrence-free survival and disease-specific survival.

conclusionsTumour size is an important prognostic factor and should be considered when determining the treatment strategy for thymoma patients.

Indexed as

ThymomaThymus NeoplasmsAdolescentAdultAgedAged, 80 and overDisease-Free SurvivalFemaleHumansMaleMiddle AgedNeoplasm StagingPrognosisProportional Hazards ModelsRetrospective StudiesYoung AdultPrognostic factorThymic epithelial tumourTumor node and metastasis (TNM) staging

Identifiers

PMID30783650

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.